



# AdisInsight

Written by scientists

- A database for drug research and development, disease treatment and decision making, based on trusted, scientifically-sound data
- Expertly reviewed, assessed and summarized by a team of scientists
- A single search delivers results on drugs, trials, deals and safety

New  
platform

**AdisInsight** brings together essential scientific information on drugs in commercial development, key clinical trials, deals and safety profiles, in one easy-to-use database.

# Welcome to AdisInsight

Whatever your involvement in the world of drug development, from a researcher to a strategist, a regulator to a healthcare provider, you will benefit from the greater perspective that AdisInsight provides.

## Make better informed decisions

Gain a greater perspective of the drug landscape with a single search working across more than 200,000 drug, trial, deal and safety records

## Gain a competitive advantage

Stay at the forefront of your area by adapting your research focus according to the most compelling new information

## Improve work efficiency

Reduce the time taken to answer critical questions with easily digestible, consolidated scientific and commercial data

## Get timely access to expert narratives

Information is assessed and consolidated from multiple sources, so you can trust the content first time around

## Align efforts to improve patient care

AdisInsight makes expertly-written drug information more accessible to everyone, no matter what your background, providing a shared knowledge base to help in translating research into practice



Adis are experts in drug evaluation with more than 40 years' experience of providing trusted, independent content

# Expertly-written content from across the drug lifecycle

## Drugs

Access leading, evidence-based scientific and market information on drugs in commercial development worldwide. Drug and cell-based products are tracked across all therapeutic areas and throughout the entire development process, from discovery to launch.

AdisInsight drug profiles include:

- Key development milestones
- Development status and history
- Drug properties
- Chemical synopses
- Pharmacokinetics data
- Pharmacodynamics data
- Company agreements
- Trial landscape and details
- Related safety reports
- Patent information
- Related drugs
- Drug limitations
- Immunogenicity

## Trials

Quickly identify the key clinical trials being performed to advance these drugs through international regulatory pathways, with coverage of both international and observational trials. Profiles include:

- Phase of trial and current status
- Trial purpose, focus and design
- Primary and other endpoints
- Diseases and subjects treated
- Inclusion and exclusion criteria
- Trial identifiers
- Organizations involved
- Initiation, completion and end dates
- Interventions
- Study center and investigator details
- Trial history
- Outcomes and results
- Related authors

## Deals

Review concise summaries of purchases and acquisitions, joint ventures, and agreements for licensing, R&D, development, manufacturing, distribution and marketing with deal values given, where available. AdisInsight can help you to keep up with the ever-changing landscape of drug development, to identify opportunities for investment, business development and collaboration, and benchmark relative deal values and terms for your own technologies.

## Safety

The most comprehensive and reliable worldwide resource for pharmacovigilance literature monitoring, AdisInsight provides fast and easy access to published adverse drug reaction (ADR) case reports, drug safety studies and regulatory news covering all drugs and therapeutic areas, updated daily. Safety records provide:

- Easy identification of serious, overdose, interaction and first published case reports
- Expert summaries of Individual Case Safety Reports (ICSRs) that comply with CIOMS II guidelines for Periodic Safety Update Reports (PSURs)
- WHO contextual adverse event data for first published case reports
- Full citation details with links to the full-text where available, to support further research
- Reports dating back to 1982

# Greater perspective leads to better decision making

AdisInsight connects the world of drug development by bringing together information from each stage of the drug lifecycle into a single database.

You can retrieve highly focused results with a single search, eliminating the need to access multiple databases.

In addition to being able to search across the whole database, content within profiles is also interlinked. For example, when reading a drug profile you can see the related trials and adverse events and link through to these related records.

By connecting this information, you can see the *big picture* of a drug or disease, providing a richer context to your research and decision making and helping you to make greater discoveries.

## Highlighted Feature: Trial Landscapes

Within a drug profile you can see a full trial landscape by phase and indication, helping you to predict what the lead indication/s may be, and assess how seriously other indications are being pursued

The screenshot displays the AdisInsight interface. On the left, the 'DRUGS' tab is active, showing the drug profile for Ramipril. On the right, the 'TRIALS' tab is active, showing a trial profile for a placebo-controlled study of ramipril. Below the trial profile, a 'Trial Overview' table is visible, which is detailed below.

Indication	Phase 0	Phase I	Phase II	Phase III	Phase IV
Acute coronary syndromes	-	-	-	1	-
Asthenozoospermia	-	-	1	-	-
Atherosclerosis	-	-	-	2	-
Atrial fibrillation	-	-	-	1	-

# What sets AdisInsight apart from other resources is our ...scientific expertise

Unlike our competitors, *we don't just "copy and paste" or add unnecessary information* in a bid to have the biggest database. Our focus is on *quality and relevance*, which is achieved by following a methodical approach to identifying, evaluating and summarizing content.



...scientific expertise

## Editorial Review

### Monitoring

We continuously monitor a variety of global sources to identify *new data*.



### Assessing

New data is reviewed and assessed to *extract relevant information*, based on its significance and scientific merit.

### Categorizing

Detailed and consistent *indexing* is applied to support highly focused searching

### Validating

Information is verified across multiple sources to *resolve discrepancies* and remove bias.

### Expert Summaries

Concise narratives tell the story, using the *most compelling evidence*, and cutting out unnecessary noise.

# Easy-to-use Platform

The simple search offers the fastest way to start exploring, with the most commonly used search criteria such as Drug Name, Mechanism of Action and Adverse Event, all available upfront.

Results are delivered across all content sets – drug profiles, clinical trials, safety reports and deals.

Intelligent search facets provide at-a-glance counts of results by key criteria and can be used to quickly refine your search

If you know exactly what you are looking for, you can build more detailed queries using the Advanced Search

Getting the answers you need from AdisInsight is simple, no matter how specific or broad your enquiry. The user-friendly platform is designed to help you find the information you need.

The screenshot displays the AdisInsight search results for the drug 'Exenatide'. The interface includes a search bar with 'Exenatide' entered and a dropdown menu set to 'by Drug Name'. Below the search bar, there are navigation links for 'Home' and 'Contact Us'. The main content area is divided into two columns. The left column, titled 'Refine Your Search', contains several facets: 'Indication' (Diabetes mellitus: 14, Metabolic disorders: 14, Type 2 diabetes mellitus: 13, Obesity: 2, Parkinson's disease: 1), 'Phase' (Marketed: 2, Registered: 2, Phase III: 3, Phase II/III: 1, Phase II: 6), 'Location' (USA: 9, China: 5, European Union: 5, South Korea: 5, Germany: 4), and 'Mechanism Of Action' (Glucagon-like peptide 1 receptor agonists: 13, Glucagon-like peptide 1 stimulants: 1, Insulinotropin agonists: 1). The right column, titled 'Search results for Drug Name: "Exenatide"', shows a summary of results: 15 Drugs, 181 Trials, 45 Safety Reports, and 9 Deals. It also indicates 'Showing 15 of 15 drugs' and provides sorting options ('Sort by: Update date') and an 'Export' button. Three search results are listed: 1. 'Exenatide long-acting release - AstraZeneca' (11 Mar 2015), 2. 'Exenatide' (10 Mar 2015), and 3. 'Exenatide sustained-release - Pepton/Yuhan Corporation' (04 Mar 2015). Each result includes details on active and inactive indications, marketed status, and originator information.

Start exploring the new AdisInsight today at [adisinsight.springer.com](http://adisinsight.springer.com)

Visit [adis.com/AdisInsight](http://adis.com/AdisInsight) or email [AdisInsight@springer.com](mailto:AdisInsight@springer.com) to request a demo or trial.

The screenshot shows the AdisInsight homepage. At the top, there is the Adis logo and a 'Login / Register' link. Below the logo is a navigation menu with links for 'Home', 'Resources', 'Products and Services', 'About Us', and 'Contact Us'. The main content area features a 'Products & services' section with links to 'Adis journals and newsletters', 'AdisInsight databases', 'New AdisInsight' (with a sub-link for 'AdisInsight for drug research'), 'Pharmacovigilance solutions', and 'Custom intelligence'. To the right, there is a section titled 'Introducing the new AdisInsight platform' with the sub-heading 'Written by scientists'. This section includes a list of bullet points: 'A database for drug development and research, disease treatment and decision making, based on trusted, scientifically sound data', 'Expertly reviewed, assessed and summarized by a team of scientists', and 'A single search can deliver results on drugs, trials, safety and deals'. A red graphic with a white triangle and dots is positioned to the right of the text. Below the text, there is a paragraph stating: 'What sets AdisInsight apart from other information resources is our scientific expertise. We don't just "cut and paste" content from external sources. Our team of expert editors review multiple sources to identify, extract and summarize the key information, cutting out the noise and making it easier for you to find what you are looking for.'